EGFR and non-small cell lung carcinoma: Clinical studies have reported that NSCLC patients harboring epidermal growth factor receptor (EGFR) mutations fail to derive clinical benefit from monotherapy with αPD-1/L1 inhibitors, regardless of PD-L1 expression levels (87–89).